Rather & Kittrell’s Quest Diagnostics DGX Stock Holding History

Rather & Kittrell’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	-$1K	–	112
2021 Q4	$1K	Buy	+10	New	+$1.52K	﹤0.01%	298

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Rather & Kittrell's DGX Position: Q1 2022 in Review

Rather & Kittrell sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 10 shares — an estimated $1K sold.

Rather & Kittrell first reported a position in DGX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

Rather & Kittrell reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
Rather & Kittrell sold 10 Quest Diagnostics shares in Q1 2022, an estimated $1K.
Rather & Kittrell first reported a position in Quest Diagnostics in Q4 2021 and held it in 1 quarter.
Rather & Kittrell's Quest Diagnostics position peaked at $1K in Q4 2021.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Rather & Kittrell's 13F filing for Q1 2022, filed 10 May 2022.